Stocks fall as slump continues 📉

The S&P 500, Dow, and Nasdaq all fell by more than a point in today's trading session.

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. 

Here’s what moved the market today.

Markets 📈

Stocks extended their weekly losses on Tuesday, with most indexes suffering losses exceeding 1%.

  • DJIA [-1.0%]

  • S&P 500 [-1.0%]

  • Nasdaq [-1.6%]

  • Russell 2K [-1.0%]

A world-famous analyst just revealed a trick he's used week after week to rack up double and triple-digit trades…

And considering that his track record boasts an amazing 97% win rate… even in today's market, I'd say it works pretty well.

Great for him - but what does that mean for YOU?

With all the uncertainty in today's economy and the stock market, he's agreed to reveal this strategy so other regular investors can use it too.

» Want an Ad-Free Experience + Top Growth Stock Picks? Upgrade Now! 

Market-Moving News 🔎 

📈 Dialysis Stocks Get a Healthy Boost

Tuesday showcased investors' keen interest in Ozempic's potential to shake up various sectors, with the dialysis industry under the microscope this time. The spotlight was on companies like Fresenius, DaVita, and Outset Medical, all of which provide crucial dialysis services.

These stocks saw a notable uptick, with Fresenius leading the pack with an 11% increase. This surge followed Novo Nordisk's release of new details from an Ozempic study targeting individuals with type 2 diabetes and chronic kidney disease.

📊 Study Revelations
While the study painted Ozempic in a positive light, showing a 24% reduction in the risk of disease progression or death, analysts were quick to point out that these benefits were at the lower end of what investors were hoping for.

This tempered expectation comes after a previous blow to dialysis stocks last year when Novo Nordisk halted the study early due to Ozempic's efficacy, leaving the results a mystery until now.

💡 Reassessing Ozempic
The latest insights into the study suggest that Ozempic might not dramatically reduce the number of patients progressing to dialysis as previously anticipated.

This revelation injected a dose of optimism into the dialysis sector, with analysts suggesting that the industry might not face as severe a downturn as feared. However, it's important to note that these aren't the complete results.

🔍 Awaiting the Full Picture
The dialysis market and investors are on the edge of their seats, waiting for the full study results to be unveiled later this year.

These findings will be crucial in fully understanding Ozempic's potential effects on the dialysis industry, offering a clearer prognosis for both patients and providers in this vital healthcare sector.

Top Winners and Losers 🔥

Airship AI [AISP] $4.95 (200.0%)
won an Dept. of Justice contract for its Acropolis enterprise video and data management platform.

BeyondSpring [BYSI] $2.90 (+76.8%)
continued to rally after regaining compliance with Nasdaq’s minimum bid price requirement last week.

Dave [DAVE] $36.00 (+64.3%)
noted a steep jump in sales on its Q4 earnings report.

QT Imaging [QTI] $1.35 (61.7%)
continues to struggle after hitting the market last week following a SPAC merger with Gig Capital5.

Quoin Pharma [QNRX] $1.50 (48.2%)
registered for a $6.5 million public offering of its shares today.

Crawford & Co. [CRD/A] $8.99 (28.1%)
reported disappointing quarterly results after Monday’s closing bell.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback from our members!

Thanks for reading. I'll see you at the next open! 

Best Regards,
Adam G.
Elite Trade Club

Text ELITESTOCKS to 47121 or click here to get our alerts on your mobile device, and never miss another fast-moving stock!

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.